Change of Registered Office

RNS Number : 9911Y
Proteome Sciences PLC
18 May 2021
 

18 May 2021

 

 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Change of Registered Office

 

The directors of Proteome Sciences announce that the Company's registered office address has changed to 5 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey, KT15 2HJ with immediate effect.

 

 

 

 

For further information:

 

Proteome Sciences plc

Dr Mariola Soehngen, Chief Executive Officer &

Dr Ian Pike, Chief Scientific Officer

 

 

Tel: +44 (0)20 7043 2116

 

Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

 

 

About Proteome Sciences plc. ( www.proteomics.com )

 

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

 

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CROFIFSTERITLIL
UK 100

Latest directors dealings